Bakuchiol compositions for treatment of post inflammatory hyperpigmentation
Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.
1. A method for alleviating, reducing or treating excess pigmentation in a deep layer of skin resulting from a condition derived from an inflammatory skin disorder, the method comprising administering to a mammal an effective amount of a composition comprising bakuchiol, or a pharmaceutically acceptable salt thereof, at least one preservative, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities.
2. The method of claim 1 , wherein the preservative comprises phenoxyethanol, chlorphenesin, or a combination thereof.
3. The method of claim 1 , wherein the at least one anti-inflammatory, anti-microbial, biocide agent, or combination thereof comprises α-hydroxyacids, salicylic acid, linoleic acid, retinoids, benzoyl peroxide, sodium sulfacetamide, clindamycin, erythromycin, dapsone, tetracycline, doxycyclin, minocyclin, zinc, estrogen and its derivatives, chlorphenesin, anti-androgens, sulfur, corticosteroids, cortisone, tazarotene, curcumin extract, acacia extract, scutellaria extract, green tea extract, grape seed extract, or a combination thereof.
4. The method of claim 1 , wherein the composition comprises less than 100 ppm total furanocoumarin impurities.
5. A composition for alleviating, reducing or treating excess pigmentation in a deep layer of skin resulting from a condition derived from an inflammatory skin disorder comprising bakuchiol, or a pharmaceutically acceptable salt thereof, at least one preservative, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities.
6. The composition of claim 5 , wherein the preservative comprises phenoxyethanol, chlorphenesin, or a combination thereof.
7. The composition of claim 5 , wherein at least one anti-inflammatory, anti-microbial, biocide agent, or combination thereof comprises α-hydroxyacids, salicylic acid, linoleic acid, retinoids, benzoyl peroxide, sodium sulfacetamide, clindamycin, erythromycin, dapsone, tetracycline, doxycyclin, minocyclin, zinc, estrogen and its derivatives, chlorphenesin, anti-androgens, sulfur, corticosteroids, cortisone, tazarotene, curcumin extract, acacia extract, scutellaria extract, green tea extract, grape seed extract, or a combination thereof.
8. The composition of claim 5 , wherein the composition comprises less than 100 ppm total furanocoumarin impurities.
9. The composition of claim 5 , wherein the composition comprises 0.001% to 99.9% by total weight of bakuchiol and a pharmaceutically, dermatologically or cosmetically acceptable carrier.
10. The composition of claim 5 , wherein the composition comprises from about 0.1% to about 2.0% by total weight of bakuchiol.
11. A method for alleviating, reducing or treating excess pigmentation in a deep layer of skin resulting from a condition derived from an inflammatory skin disorder, the method comprising administering to a mammal an effective amount of a composition comprising bakuchiol, or a pharmaceutically acceptable salt thereof, at least one anti-inflammatory, anti-microbial, biocide agent, or combination thereof, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities.
12. The method of claim 11 , wherein the composition comprises less than 100 ppm total furanocoumarin impurities.
13. A composition for alleviating, reducing or treating excess pigmentation in a deep layer of skin resulting from a condition derived from an inflammatory skin disorder comprising bakuchiol, or a pharmaceutically acceptable salt thereof, at least one anti-inflammatory, anti-microbial, biocide agent, or combination thereof, and a pharmaceutically acceptable carrier and less than 500 ppm total furanocoumarin impurities.
14. The composition of claim 13 , wherein the composition comprises less than 100 ppm total furanocoumarin impurities.
15. The composition of claim 13 , wherein the composition comprises 0.001% to 99.9% by total weight of bakuchiol and a pharmaceutically, dermatologically or cosmetically acceptable carrier.
16. The composition of claim 13 , wherein the composition comprises from about 0.1% to about 2.0% by total weight of bakuchiol.